Open Targets is a public-private partnership made up of four global leading institutions in the fields of pharmaceuticals, bioinformatics and genomics, namely GSK, EMBL-EBI, the Wellcome Trust Sanger Institute, and Biogen. We combine large-scale genomic experiments to identify and validate the causal links between targets, pathways and diseases. We have recently developed the Target Validation platform, a web application for data integration and visualisation, which supports both target- and disease-centric workflows.
Mr. Ong Chuang Kee
Data Integration Manager
European Bioinformatics Institute (EMBL-EBI)
Chuang Kee is a proven research and informatics leader using computational and informatics platforms for life science and drug discovery applications. In his role as Data Integration Manager at OpenTargets (EBI), Chuang Kee manages data providers across various different groups and leads the data integration efforts. Chuang Kee join OpenTargets from Ensembl. Most recently the Senior Technical Officer in the production team, responsible for the large scale genomics processing pipelines, production infrastructure development, data coordination among various sub-teams to ensure timely delivery of Ensembl releases consist of thousands genomes. Before Ensembl, Chuang Kee was the Principal Scientist, VP at SDTC. He is responsible for the bioinformatics unit whose efforts were geared toward enhancing palm oil yield productivity via various cutting-edge high throughput assays. Prior to joining SDTC, Chuang Kee was the Senior Associate Scientists at Eli Lilly. He lead various cross functional, disciplines drug discovery informatics projects to support target identifications and validation in a variety of therapeutic areas. Chuang Kee has a MSc Bioinformatics from Chalmers University of Technology in Sweden.